In this single-group , open-label , phase @ study , @ patients with indolent non-Hodgkin 's lymphomas who had not had a response to rituximab and an alkylating agent or had had a relapse within @ months after receipt of those therapies were administered idelalisib , @ mg twice daily , until the disease progressed or the patient withdrew from the study .